67 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 19326445 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | SAMALA, JAGADISHWAR RAO | 1618 | Non-Final OA | Sep 11, 2025 |
| 19240908 | METHOD OF TREATING PROSTATE CANCER | PERREIRA, MELISSA JEAN | 1618 | Final Rejection | Jun 17, 2025 |
| 19234864 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | MEJIAS, SAMANTHA LEE | 1618 | Non-Final OA | Jun 11, 2025 |
| 19176436 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | YOUNG, MICAH PAUL | 1618 | Non-Final OA | Apr 11, 2025 |
| 18977210 | Ribociclib Tablet | FUBARA, BLESSING M | 1613 | Non-Final OA | Dec 11, 2024 |
| 18667421 | DIGITAL SOLUTIONS FOR DIFFERENTIATING ASTHMA FROM COPD | GILLIGAN, CHRISTOPHER L | 3683 | Final Rejection | May 17, 2024 |
| 18629314 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | HUYNH, PHUONG N | 1641 | Non-Final OA | Apr 08, 2024 |
| 18628570 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | SAMALA, JAGADISHWAR RAO | 1618 | Non-Final OA | Apr 05, 2024 |
| 18694271 | A COMPUTER IMPLEMENTED METHOD FOR ASSESSING AND DETERMINING A COMPLEXITY LEVEL OF A CLINICAL TRIAL STUDY | WEBB, JESSICA MARIE | 3683 | Non-Final OA | Mar 21, 2024 |
| 18609420 | METHODS OF TREATING METABOLIC DISORDERS ASSOCIATED WITH LIPODYSTROPHIES AND DEFECTS IN INSULIN PRODUCTION OR SIGNALING | SAOUD, CHRISTINE J | 1645 | Non-Final OA | Mar 19, 2024 |
| 18588259 | Ribociclib Tablet | FUBARA, BLESSING M | 1613 | Non-Final OA | Feb 27, 2024 |
| 18440783 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | SAMALA, JAGADISHWAR RAO | 1618 | Final Rejection | Feb 13, 2024 |
| 18426461 | Novel Heteroaryl Aminopropanol Derivatives | HABTE, KAHSAY | 1624 | Non-Final OA | Jan 30, 2024 |
| 18569432 | METHOD OF TREATING AN AUTOIMMUNE HEMATOLOGICAL DISORDER | OH, TAYLOR V | 1625 | Non-Final OA | Dec 12, 2023 |
| 18561444 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | RAO, SAVITHA M | 1691 | Non-Final OA | Nov 16, 2023 |
| 18510836 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | LEWIS, PATRICK T | 1691 | Non-Final OA | Nov 16, 2023 |
| 18504244 | Tetrahydro-Pyrido-Pyrimidine Derivatives | MOORE, SUSANNA | 1624 | Non-Final OA | Nov 08, 2023 |
| 18558766 | IPTACOPAN FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME | HERNANDEZ, JACKSON J | 1627 | Non-Final OA | Nov 03, 2023 |
| 18558415 | ALPELISIB FORMULATION | JUSTICE, GINA CHIEUN YU | 1617 | Non-Final OA | Nov 01, 2023 |
| 18557772 | HYPERSIALYLATING CELLS | BERKE-SCHLESSEL, DAVID W | 1651 | Non-Final OA | Oct 27, 2023 |
| 18554778 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | BORALSKY, LUKE ALAN | 1624 | Non-Final OA | Oct 10, 2023 |
| 18286030 | OFATUMUMAB FOR TREATING MULTIPLE SCLEROSIS IN ASIAN PATIENTS | CHHAY, BONIRATH | 1645 | Non-Final OA | Oct 06, 2023 |
| 18551699 | NOVEL CYCLOPENTA[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | RAO, PADMAJA S | 1627 | Non-Final OA | Sep 21, 2023 |
| 18551739 | "Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B" | SHIM, DAVID M. | 1626 | Non-Final OA | Sep 21, 2023 |
| 18551033 | NEW PROCESS FOR THE SYNTHESIS OF 5-{5-CHLORO-2-[(3S)-3-[(MORPHOLIN-4-YL)METHYL]-3,4-DIHYDROISOQUINOLINE-2(1H)- CARBONYL]PHENYL}-1,2-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND ITS APPLICATION FOR THE PRODUCTION OF PHARMACEUTICAL COMPOUNDS | SEAMAN, D MARGARET M | 1625 | Non-Final OA | Sep 18, 2023 |
| 18550004 | HIGH THROUGHOUT SCREENING IN DROPLETS | BUNKER, AMY M | 1684 | Non-Final OA | Sep 11, 2023 |
| 17997137 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | SKOKO III, JOHN JOSEPH | 1643 | Non-Final OA | Aug 08, 2023 |
| 18363207 | NLRP3 INFLAMMASOME INHIBITORS | HEES, OLIVER DRAGON | 1628 | Non-Final OA | Aug 01, 2023 |
| 18261523 | PHARMACEUTICAL COMPOSITION | GOTFREDSON, GAREN | 1619 | Non-Final OA | Jul 14, 2023 |
| 18251913 | ANTIBODY Fc VARIANTS | HOWARD, ZACHARY C | 1674 | Non-Final OA | May 05, 2023 |
| 18035472 | ANTI-CD19 AGENT AND B CELL TARGETING AGENT COMBINATION THERAPY FOR TREATING B CELL MALIGNANCIES | NATARAJAN, MEERA | 1643 | Non-Final OA | May 04, 2023 |
| 18178886 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | HUYNH, PHUONG N | 1641 | Final Rejection | Mar 06, 2023 |
| 18023212 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | LIU, TRACY | 1614 | Non-Final OA | Feb 24, 2023 |
| 18019467 | TREATMENT OF CLL | KAUFMAN, CLAIRE M | 1674 | Final Rejection | Feb 02, 2023 |
| 18019469 | TREATMENT OF B CELL MALIGNANCIES | KAUFMAN, CLAIRE M | 1674 | Final Rejection | Feb 02, 2023 |
| 18006894 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | TOWNSLEY, SARA ELIZABETH | 1629 | Final Rejection | Jan 26, 2023 |
| 18005364 | MAVOGLURANT, A MGLUR5 ANTAGONIST, FOR USE IN THE TREATMENT IN THE REDUCTION OF OPIOID USE | HOWELL, THEODORE R | 1628 | Final Rejection | Jan 13, 2023 |
| 18002572 | ORAL LIQUID FORMULATIONS OF RUXOLITINIB | CORNET, JEAN P | 1628 | Final Rejection | Dec 20, 2022 |
| 17998391 | THERAPEUTIC COMBINATIONS COMPRISING A CRAF INHIBITOR | MCKOY, QUINCY ANDRE | 1626 | Final Rejection | Nov 10, 2022 |
| 17997482 | ENGINEERED IMMUNOGLOBULINS | NATARAJAN, MEERA | 1643 | Non-Final OA | Oct 28, 2022 |
| 17997295 | METHODS FOR RADIOLABELLING PSMA BINDING LIGANDS AND THEIR KITS | DONOHUE, SEAN R | 1618 | Final Rejection | Oct 27, 2022 |
| 17997299 | METHODS FOR RADIOLABELING PSMA BINDING LIGANDS AND THEIR KITS | DONOHUE, SEAN R | 1618 | Final Rejection | Oct 27, 2022 |
| 17938846 | METHODS OF TREATING NEW-ONSET PLAQUE TYPE PSORIASIS USING IL-17 ANTAGONISTS | JIANG, DONG | 1674 | Non-Final OA | Oct 07, 2022 |
| 17995820 | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG | WANG, CHANG YU | 1675 | Non-Final OA | Oct 07, 2022 |
| 17820005 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | VANHORN, ABIGAIL LOUISE | 1636 | Non-Final OA | Aug 16, 2022 |
| 17760298 | THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR FOR USE IN TREATING BRAF MUTANT NSCLC | ROBINSON, MIKHAIL O'DONNEL | 1627 | Final Rejection | Aug 05, 2022 |
| 17853537 | Pharmaceutical Compositions Comprising Alpelisib | NEAGU, IRINA | 1629 | Final Rejection | Jun 29, 2022 |
| 17786347 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | HILL, KEVIN KAI | 1638 | Non-Final OA | Jun 16, 2022 |
| 17773935 | TREATMENT FOR SJÖGREN'S SYNDROME USING AN ANTI-BAFFR ANTIBODY | KAUFMAN, CLAIRE M | 1674 | Non-Final OA | May 03, 2022 |
| 17754059 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | YOUNG, MICAH PAUL | 1618 | Final Rejection | Mar 22, 2022 |
| 17753850 | METHODS FOR RADIOLABELLING GRPR ANTAGONISTS AND THEIR KITS | MEJIAS, SAMANTHA LEE | 1618 | Final Rejection | Mar 16, 2022 |
| 17642292 | GLUE DEGRADERS AND METHODS OF USE THEREOF | HEITMEIER, KENDALL NICOLE | 1621 | Final Rejection | Mar 11, 2022 |
| 17753635 | Management of conditions other than multiple sclerosis in ofatumumab-treated patients | WANG, CHANG YU | 1675 | Non-Final OA | Mar 09, 2022 |
| 17640293 | THERAPEUTIC FUSION PROTEINS | DEBERRY, REGINA M | 1647 | Final Rejection | Mar 03, 2022 |
| 17639862 | TREATMENT OF LIVER DISEASE OR DISORDER COMPRISING ACTRII RECEPTOR ANTAGONISTS | SAOUD, CHRISTINE J | 1645 | Final Rejection | Mar 02, 2022 |
| 17629286 | REGULATABLE EXPRESSION SYSTEMS | LEVIN, JOEL D | 1633 | Final Rejection | Jan 21, 2022 |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | NICKOL, GARY B | 1643 | Non-Final OA | Dec 20, 2021 |
| 17613889 | METHOD FOR NAVIGATING MEDICAL DATA | LAM, ELIZA ANNE | 3681 | Non-Final OA | Nov 23, 2021 |
| 17612280 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | VAN DRUFF, SYDNEY | 1643 | Non-Final OA | Nov 18, 2021 |
| 17609261 | ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF TIDM AND INSULITIS | BERHANE, SELAM | 1675 | Final Rejection | Nov 05, 2021 |
| 17433812 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | EBBINGHAUS, BRIANA NOEL | 1632 | Non-Final OA | Aug 25, 2021 |
| 17421747 | LTA4H INHIBITORS FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA | CHANNAVAJJALA, LAKSHMI SARADA | 1611 | Final Rejection | Jul 09, 2021 |
| 17309403 | AAV VIRAL VECTORS AND USES THEREOF | RIGA, MICHAEL ANGELO | 1634 | Non-Final OA | May 25, 2021 |
| 17292881 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | SCHMIDT, IZABELA MARIA | 1621 | Non-Final OA | May 11, 2021 |
| 17161929 | CHO CELL EXPRESSED HET IL-15 | CARTER, SANDRA DILLAHUNT | 1674 | Non-Final OA | Jan 29, 2021 |
| 16761513 | METHOD OF TREATING HIDRADENTITIS SUPPURATIVA WITH IL-17 ANTAGONISTS | DEBERRY, REGINA M | 1647 | Final Rejection | May 05, 2020 |
| 16608515 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | LU, CHENG | 1642 | Non-Final OA | Oct 25, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial